Purpose of this Study
We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiple myeloma patients live longer.
Who Can Participate?
Eligibility
Adults with multiple myeloma who have had a stem cell transplant.
Age Range
18-75
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will get a random assignment (like flipping a coin) to 1 of 2 groups:
One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
The other group will take lenalidomide alone
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator
Taewoong
Choi
Protocol Number
PRO00104040
NCT ID
NCT04071457
Phase
III
Enrollment Status
Open to Enrollment